Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy
- K. Pasi, S. Rangarajan, M. Ragni
- Medicine, BiologyNew England Journal of Medicine
- 10 July 2017
Once‐monthly subcutaneous administration of fitusiran resulted in dose‐dependent lowering of the antithrombin level and increased thrombin generation in participants with hemophilia A or B who did not have inhibitory alloantibodies.
Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors
- B. Konkle, L. S. Ebbesen, M. Serban
- MedicineJournal of Thrombosis and Haemostasis
- 1 September 2007
Clinically relevant reductions in bleeding frequency during prophylaxis as compared to conventional on‐demand therapy were achieved without raising safety concerns, providing evidence for the concept of secondary rFVIIa prophyllaxis in inhibitor patients with frequent bleeds.
Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.
- E. Santagostino, U. Martinowitz, I. Jacobs
- MedicineBlood
- 7 April 2016
Results indicate rIX-FP is safe and effective for preventing and treating bleeding episodes in patients with hemophilia B at dosing regimens of 40IU/kg weekly and 75 IU/kg every 2 weeks.
Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial
- W. Knauf, T. Lissitchkov, M. Montillo
- MedicineBritish Journal of Haematology
- 1 October 2012
Bendamustine should be considered as a preferred first‐line option over chlorambucil for CLL patients ineligible for fludarabine, cyclophosphamide and rituximab.
Randomized, controlled, parallel‐group trial of routine prophylaxis vs. on‐demand treatment with sucrose‐formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)
- M. Manco-Johnson, C. Kempton, W. Hong
- MedicineJournal of Thrombosis and Haemostasis
- 1 June 2013
The benefits of routine prophylaxis vs. on‐demand treatment with factor VIII products have not been evaluated in controlled clinical trials in older patients with hemophilia A.
Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C)…
- T. Lissitchkov, G. Arnaudov, D. Peytchev, K. Merkle
- MedicineJournal of Cancer Research and Clinical Oncology
- 1 February 2006
First-line use of bendamustine is a safe option for CLL-patients requiring treatment, because it is highly effective, reasonably safe, and does hardly produce cross-resistance against other anti-neoplastic drugs effective in this indication.
Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or…
- J. Windyga, T. Lissitchkov, B. Abbuehl
- Medicine, BiologyHaemophilia
- 1 January 2014
It is indicated that BAX326 is safe and efficacious in treating bleeds and routine prophylaxis in patients aged 12 years and older with haemophilia B.
Prophylaxis vs. on‐demand treatment with Nuwiq® (Human‐cl rhFVIII) in adults with severe haemophilia A
- A. Tiede, J. Oldenburg, T. Lissitchkov, S. Knaub, J. Bichler, M. Manco-Johnson
- Medicine, BiologyHaemophilia
- 1 May 2016
Haemophilia A is treated with FVIII, either prophylactically or on demand. Prophylaxis is the gold standard in children and evidence is accumulating in adults.
Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma.
- S. Rao, D. Watkins, J. Holmlund
- MedicineAnnals of Oncology
- 1 September 2004
ISIS 3521 has demonstrated anti-tumour activity in patients with relapsed low- grade NHL and there may be a potential role for this agent in combination with conventional chemotherapy for advanced low-grade lymphoma, and further trials are warranted.
Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients
- U. Martinowitz, T. Lissitchkov, E. Santagostino
- BiologyHaemophilia
- 20 May 2015
rIX‐FP is a coagulation factor IX (recombinant), albumin fusion protein with more than fivefold half‐life prolongation over other standard factor IX (FIX) products available on the market.
...
...